María Varela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
María Varela has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Diego Alem
Epigenetics and Genomic Instability Laboratory, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay
1 shared publication - Gloria V. Lopez
Organic Synthesis and Drug Development Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay; Departamento de Química Orgánica, Facultad de Química, Universidad de La República, Montevideo, Uruguay
1 shared publication - Karen Perelmuter
Cell Biology Unit, Institut Pasteur de Montevideo, Mataojo 2020, Montevideo 11400, Uruguay
1 shared publication - Mariana Ingold
Laboratorio de Biología Vascular y Desarrollo de Fármacos, Institut Pasteur Montevideo, Mataojo 2020, Montevideo 11400, Uruguay
1 shared publication - Mariela Bollati-Fogolín
Cell Biology Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay
1 shared publication - Miriam López
Departamento de Genética, Instituto de Investigaciones Biológicas Clemente Estable, Avenida Italia 3318, Montevideo 11600, Uruguay
1 shared publication
Latest Publications
- Open Access
- 12 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 199
New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs
Bladder cancer is a worldwide problem and improved therapies are urgently needed. In the search for newer strong antitumor compounds, herein, we present the study of three nitric oxide-releasing compounds and evaluate them as possible therapies for this malignancy. Bladder cancer cell lines T24 and 253J were used to evaluate the antiproliferative, antimigratory, and genotoxic effects of compounds. Moreover, we determined the NF-κB pathway inhibition, and finally, the survivin downregulation exerted by our molecules. The results revealed that compounds 1 and 3 exerted a high antiproliferative activity against bladder cancer cells through DNA damage and survivin downregulation. In addition, compound 3 reduced bladder cancer cell migration. We found that nitric oxide donors are promising molecules for the development of a new therapeutic targeting the underlying mechanisms of tumorigenesis and progression of bladder cancer.
- 12 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 199
Open AccessNew Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs
Bladder cancer is a worldwide problem and improved therapies are urgently needed. In the search for newer strong antitumor compounds, herein, we present the study of three nitric oxide-releasing compounds and evaluate them as possible therapies for this malignancy. Bladder cancer cell lines T24 and 253J were used to evaluate the antiproliferative, antimigratory, and genotoxic effects of compounds. Moreover, we determined the NF-κB pathway inhibition, and finally, the survivin downregulation exerted by our molecules. The results revealed that compounds 1 and 3 exerted a high antiproliferative activity against bladder cancer cells through DNA damage and survivin downregulation. In addition, compound 3 reduced bladder cancer cell migration. We found that nitric oxide donors are promising molecules for the development of a new therapeutic targeting the underlying mechanisms of tumorigenesis and progression of bladder cancer.